Shopping Cart
- Remove All
- Your shopping cart is currently empty
NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $586 | 6-8 weeks | |
25 mg | $1,670 | 6-8 weeks | |
50 mg | $2,180 | 6-8 weeks | |
100 mg | $2,800 | 6-8 weeks |
Description | NXT629 is a selective and competitive antagonist of PPAR-α(human PPARα with an IC50 of 77 nM). |
Targets&IC50 | PPARα (human):77 nM, GR:32.5 μM, PPARδ (human):6 μM, ERβ:15.2 μM, PPARγ (human):15 μM |
In vitro | NXT629 is a potent and selective antagonist of PPAR-α(human PPARα,IC50 of 77 nM), shows high selectivity over other nuclear hormone receptor, [2]. |
In vivo | NXT629 has poor oral bioavailability in mice and rats.?NXT629 (30 mg/kg, i.p., daily for 6 weeks) delays growth of subcutaneous SKOV-3 tumors in nude mice, inhibits growth of subcutaneous B16F10 tumors in C57Bl/6 mice.?NXT629 (30 mg/kg, i.p.) is weakly anti-angiogenic against FGF-induced angiogenesis.?NXT629 (3, 30 mg/kg, i.p.) inhibits experimental metastasis of B16F10 melanoma cells to the mouse lung[2]. |
Molecular Weight | 609.78 |
Formula | C35H39N5O3S |
Cas No. | 1454925-59-7 |
Smiles | CCn1c(CCCc2ccc(cc2)-c2ccc(NS(=O)(=O)c3ccccc3)cn2)nn(Cc2ccc(cc2)C(C)(C)C)c1=O |
Relative Density. | 1.20 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (204.99 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.